Original Article | Published:

Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition

Oncogene volume 37, pages 897911 (15 February 2018) | Download Citation

Abstract

Malignant melanoma reveals rapidly increasing incidence and mortality rates worldwide. By now, BRAF inhibition is the standard therapy for advanced melanoma in patients carrying BRAF mutations. However, only approximately 50% of melanoma patients harbor therapeutically attackable BRAF mutations, and overall survival after treatment with BRAF inhibitors is modest. KRAS (Kirsten Rat sarcoma) proteins are acting upstream of BRAF and have a major role in human cancer. Recent approaches awaken the hope to use KRAS inhibition (KRASi) as a clinical tool. In this study, we identified wild-type KRAS as a novel therapeutic target in melanoma. KRASi functions synergistically with BRAF inhibition to reduce melanoma proliferation and to induce apoptosis independently of BRAF mutational status. Moreover, acquired resistance to BRAF inhibitors in melanoma is dependent on dynamic regulation of KRAS expression with subsequent AKT and extracellular-signal regulated kinase activation and can be overcome by KRASi. This suggests KRASi as novel approach in melanoma—alone or in combination with other therapeutic regimes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , . Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810: 120–140.

  2. 2.

    , , , , , et al. Treatment patterns of advanced malignant melanoma (stage III-IV) - a review of current standards in Europe. Eur J Cancer 2016; 60: 179–189.

  3. 3.

    , , , , . Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii86–vii91.

  4. 4.

    , , , , , et al. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med 2016; 213: 1133–1139.

  5. 5.

    , , , , , et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med 2013; 210: 581–603.

  6. 6.

    , , . A review of novel therapies for melanoma. Am J Clin Dermatol 2014; 15: 323–337.

  7. 7.

    , . New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014; 6: 77–88.

  8. 8.

    , , , , , et al. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am J Cancer Res 2015; 5: 1507–1518.

  9. 9.

    , , . Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013; 19: 1401–1409.

  10. 10.

    , , , , , et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973–977.

  11. 11.

    , , , , , et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013; 3: 338–349.

  12. 12.

    . KRAS as a therapeutic target. Clin Cancer Res 2015; 21: 1797–1801.

  13. 13.

    , , . Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin Cancer Res 2015; 21: 1819–1827.

  14. 14.

    , , , . Dragging Ras back in the ring. Cancer Cell 2014; 25: 272–281.

  15. 15.

    , , , , , et al. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 2014; 157: 459–471.

  16. 16.

    , , , , , et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 2013; 497: 638–642.

  17. 17.

    , , , , , et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov 2014; 4: 1182–1197.

  18. 18.

    , , , , , et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA 2014; 111: E3553–E3561.

  19. 19.

    , , , , , et al. Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma. J Invest Dermatol 2015; 135: 2475–2483.

  20. 20.

    , , , , , et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010; 70: 5549–5557.

  21. 21.

    , , , , , et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005; 23: 8048–8056.

  22. 22.

    , . Microvessel density for melanoma prognosis. Histopathology 2005; 47: 186–194.

  23. 23.

    , , , , , et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683–695.

  24. 24.

    , , , , , et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 2013; 4: 1090–1099.

  25. 25.

    , . Therapeutic advances and treatment options in metastatic melanoma. JAMA Oncol 2015; 1: 380–386.

  26. 26.

    , , , . The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120: 3446–3456.

  27. 27.

    , , , , , et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010; 8: 39.

  28. 28.

    , , , , , et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 2015; 135: 532–541.

  29. 29.

    , , , , , . Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. Target Oncol 2015; 10: 77–84.

  30. 30.

    , . That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol 2013; 169: 1708–1722.

  31. 31.

    , , . Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546–5556.

  32. 32.

    , , , , , . MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000; 79: 355–369.

  33. 33.

    , , , , , . RLIP76-dependent suppression of PI3K/AKT/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer. Biochem Biophys Res Commun 2015; 463: 900–906.

  34. 34.

    , , , , , et al. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 2014; 25: 243–256.

  35. 35.

    , , . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761–774.

  36. 36.

    , , , , , et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613–617.

  37. 37.

    , , . Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Commun 2012; 3: 1168.

  38. 38.

    , , , , , et al. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol 2015; 12: 016008.

  39. 39.

    , , , , , et al. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clin Cancer Res 2015; 22: 374–382.

  40. 40.

    , , , , , et al. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front Oncol 2015; 5: 135.

  41. 41.

    , . Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol 2015; 16: 281–298.

  42. 42.

    , , , , , et al. Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes. Cancer Cell 2015; 28: 170–182.

  43. 43.

    , , , . BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin Pharmacother 2015; 16: 1285–1297.

  44. 44.

    , , . Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev 2015; 41: 519–526.

  45. 45.

    , , , , , . Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors. Mol Cancer Ther 2015; 14: 2700–2711.

  46. 46.

    , , , , , et al. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci USA 2015; 112: E536–E545.

  47. 47.

    , , , , , et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4: 80–93.

  48. 48.

    , , , , , et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015; 162: 1271–1285.

  49. 49.

    , , , , , et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 2014; 13: 2793–2804.

  50. 50.

    , , , , , et al. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J Clin Oncol 2015; 33: e52–e56.

  51. 51.

    The KRAS-PDEdelta interaction is a therapeutic target. Cancer Discov 2013; 3: OF20.

  52. 52.

    , . The renaissance of Ras. ACS Chem Biol 2014; 9: 2447–2458.

  53. 53.

    . Cancer: the Ras renaissance. Nature 2015; 520: 278–280.

  54. 54.

    , , , , , et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 2015; 22: 1499–1509.

  55. 55.

    , , , , . Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014; 211: 715–725.

Download references

Acknowledgements

This work was supported by the German Research Association (DFG) (Research Training Group ‘RTG 1962/1’, University of Erlangen), the German Cancer Aid (Deutsche Krebshilfe), the Bavarian Research Network for Molecular Biosystems (BioSysNet) and the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (J55, to PD and D24, to AB). We thank Meenhard Herlyn (The Wistar Institute, Philadelphia, USA) for providing the resistant cell lines. Furthermore, we thank Rudolf Jung, Annette Serwotka and Darleen Schönwälder for technical assistance.

Author contributions

PD, CH and AKB conceived the project, analyzed the data and wrote the paper. PD designed and performed most of the experiments. TS helped in planning and performing mouse experiments. SK contributed to data analysis and manuscript creation.

Author information

Affiliations

  1. Institute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

    • P Dietrich
    • , S Kuphal
    • , C Hellerbrand
    •  & A K Bosserhoff
  2. Institute of Pharmacy, University of Regensburg, Regensburg, Germany

    • T Spruss
  3. Comprehensive Cancer Center (CCC) Erlangen-EMN, Erlangen, Germany

    • C Hellerbrand
    •  & A K Bosserhoff

Authors

  1. Search for P Dietrich in:

  2. Search for S Kuphal in:

  3. Search for T Spruss in:

  4. Search for C Hellerbrand in:

  5. Search for A K Bosserhoff in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to A K Bosserhoff.

Supplementary information

Glossary

AKT

v-akt murine thymoma viral oncogene

BRAF

v-Raf murine sarcoma viral oncogene homolog B

BRAFi

BRAF inhibition/inhibitor

CTR

control

DR

Deltarasin

ERK

extracellular-signal regulated kinase

KR

KRAS (Kirsten Rat sarcoma)

KRASi

KRAS inhibition/inhibitor

MAPK

mitogen-activated protein kinase

MEK

mitogen-activated protein kinase kinase

MEKi

MEK inhibition/inhibitor

NRAS

neuroblastoma RAS viral oncogene homolog

PI3K

phosphatidylinositol-4,5-bisphosphate 3-kinase

PLX

PLX-4032 (Vemurafenib).

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/onc.2017.391

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)